Had a prior liver transplant or is likely to undergo liver transplantation during the study;

Has known other (non-hATTR) forms of amyloidosis or leptomeningeal amyloidosis;

Has New York Heart Association heart failure classification \>2;

Clinically significant liver function test abnormalities;

Has known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV) infection;

Received an experimental drug within 30 days of dosing;

Received prior TTR-lowering treatment;

Has other known causes of neuropathy.

HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)